While specific and selective pharmacological blockade of the PPP in vivo remains challenging, we provide evidence to demonstrate the antitumor effect of G6PD blockade in vivo in prostate cancer bone metastasis, supporting the growing interest in targeting metabolic reprogramming for the prevention and/or treatment of prostate and other cancers. The gene discussed is G6PD; the disease is cancer.